The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Bexxar
Synonyms :
tositumomab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Bexxar
Synonyms :
tositumomab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths
Injectable solution
14 mg/ml
Dosimetric dose:
450
mg
Intravenous (IV)
infuse over 1 hour
next I-131 tositumomab five mCi I-131 + 35 mg protein Intravenous (IV) infusion for 20 minutes
Therapeutic dose:
450 mg Intravenous (IV) infuse over 1 hour, next I-131 tositumomab dose determined to produce 75 cGy total body irradiation for patients with average platelet count 7 -14 days after a dosimetric dose
Safety and efficacy are not studied
Refer adult dosing
it may enhance the adverse effects when combined with aducanumab
It attaches itself to the CD20 antigen present on fully developed B cells.
It appears that the antibody binding causes complement-dependent cytotoxicity, apoptosis, and ionizing radiation-induced cell death.
Frequency defined
1-10%
Hypotension
vasodilation
Sweating
dyspepsia
Hypothyroidism
>10%
Rash, pruritus
Abdominal pain
nausea
vomiting
diarrhea
anorexia
Myalgia
arthralgia
Frequency not defined
Infusion reaction
Secondary leukemia
myelodysplastic syndrome
None
Contraindication:
None
Caution:
Bone Marrow Suppression
Secondary Malignancies
Hypothyroidism
Radiation Exposure
Pregnancy warnings:
FDA pregnancy category: D
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Mature B cells and more than 90% of B-cell non-Hodgkin’s lymphomas express the CD20 antigen, which is bound by tositumomab.
B-cells are killed selectively by the antibody.
Administer over 1 hour through intravenous infusion.
The dosimetric dose of I-131 tositumomab should be administered 30 minutes later.
A combination of radiolabeled Iodine-131 (I-131) tositumomab and unlabeled (cold) tositumomab are used in the Bexxar treatment regimen.
Patient information leaflet
Generic Name: tositumomab
Why do we use tositumomab?
Tositumomab is indicated for treatment of non-Hodgkin’s lymphoma.
For adults whose CD20-positive follicular lymphoma has returned or who are not responding to rituximab or other forms of treatment.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
